MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn moreSince its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
Learn more February 19, 2013 | BioWorld
Bispecific Antibodies Capturing Great Deal of Industry Interest
January 07, 2013 | Washington Business Journal
MacroGenics Could Get $1B Payday
January 07, 2013 | Dow Jones Business News
MacroGenics Strikes Another Deal; Gilead Alliance Could Yield More Than $1 Billion
January 07, 2013 | BioCentury Extra
MacroGenics, Gilead in mAb DART Deal
January 07, 2013 | Fierce Biotech
Gilead and Biotech Strike Antibody Deal Worth North of $1.1B--Maybe
January 07, 2013 | BioWorld
MacroGenics DART Platform Grabs Potential $1B Gilead Deal
November 19, 2012 | The Pink Sheet
How to Place Bets on Early Oncology Assets
October 01, 2012 | Drug Discovery News
A Picture Perfect Focus
September 27, 2012 | Fierce Biotech
10 Next-gen Biologics Platforms to Watch
September 21, 2012 | "The Pink Sheet" Daily
MacroGenics Strikes Second Oncology Partnership with Servier
News Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All